Conditions: Single Umbilical Cord Blood Transplantation Non-myeloablative Conditioning Acute Lymphocytic Leukemia Myelodysplastic Syndrome Non-Hodgkin's Lymphoma Multiple Myeloma Chronic Lymphocytic Leukemia
Keywords: HSC835 single umbilical cord blood transplantation non-myeloablative conditioning regimen Umbilical cord blood UCB transplantation
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 9
Healthy volunteers: no

Brief summary:
This study was designed to evaluate the safety and tolerability of HSC835 for clinical use as measured by the absence of graft failure at day 42 in excess of that currently observed with double umbilical cord blood (UCB) transplantation (DUCBT) with non-myeloablative (NMA) conditioning.

Detailed description:

Arms:
arm 1: Patients with hematologic malignancies requiring UCB transplant with a NMA conditioning regimen.

Interventions: intervention 1: HSC835
Intervention descriptions: intervention 1: HSC835 is a stem cell therapy product providing a source of Hematopoietic stem cell (HSC).

Protocol document: